Pramlintide Acetate CAS 196078-30-5 is an antidiabetic agent that can also be used in bowel cancer research

Pramlintide Acetate CAS 196078-30-5 is an antidiabetic agent that can also be used in bowel cancer research

Product Name: Pramlintide acetate
Synonyms: AMYLIN (HUMAN), 25-L-PROLINE-28-L-PROLINE-29-L-PROLINE-, ACETATE (SALT), HYDRATE;pramlintide acetate;pramlintide acetate hydrate;25-L-Proline-28-L-proline-29-L-proline-aMylin (huMan) Acetate Hydrate;AC-137 Acetate Hydrate, SyMlin Acetate Hydrate;Tripo-aMylin Acetate Hydrate;Pramlintide Acetate, Amylin Rat;Pramlintide acetate fandachem
CAS: 196078-30-5
MF: C173H273N51O56S2
MW: 4027.46
EINECS:
Product Categories: Amino Acids & Derivatives;Bases & Related Reagents;Drug Analogues;Heterocycles;Intermediates & Fine Chemicals;Nucleotides;Peptide;Pharmaceuticals
Mol File: 196078-30-5.mol

Pramlintide acetate is an injectable human amylin analog that has been launched for the treatment of both type 1 and type 2 diabetes, in conjunction with insulin. While it is also a 37-amino acid peptide, it differs from its parent predecessor by the substitution of Ala-25, Ser-28, and Ser-29 with prolines. Not only do these modifications improve the solubility of the peptide, they also eliminate the aggregation observed with amylin, resulting in a stable synthetic analog with retention of biological activity that is suitable for pharmaceutical use. As an indication of potency, Pramlintide acetate inhibits the binding of radioiodinated rat amylin to rat nucleus accumbens membranes with a Ki value of 23 pM. Its mechanism of action mimics amylin; as a neurohormone that is cosecreted with insulin from the pancreatic β cells in response to meals, it is involved in glucose homeostasis. Both peptides lower postprandial glucose levels by inhibiting glucagon and by restraining the vagus-mediated rate of gastric emptying, thereby, slowing intestinal carbohydrate absorption. Furthermore, amylin, orPramlintide acetate, has the added benefit of inducing postprandial satiety resulting in weight loss in the patients with type 2 diabetes. Since Pramlintide acetate slows gastric emptying, it is contraindicated in patients with gastroparesis and in patients taking drugs that alter gastrointestinal motility (anticholinergic agents, such as, atropine) or slow down the intestinal absorption of nutrients (such as α-glucosidase inhibitors). Pramlintide acetate is also contraindicated in patients with hypoglycemic tendencies; due to co-administration with insulin, severe insulin-induced hypoglycemia is a risk. The most commonly reported adverse events include nausea, vomiting, anorexia, headache, abdominal pain, fatigue, dizziness, coughing, and pharyngitis.

Function and Application of CAS 196078-30-5

Pramlintide acetate is a synthetic analogue of pancreatic amyloid polypeptide (Amylin, amylopectin) and is the second drug approved for the treatment of type 1 diabetes after insulin. In clinical practice, pramlintide is used as an adjuvant drug for the treatment of type 1 and type 2 diabetes, mainly for patients with diabetes who have failed to achieve the expected results with insulin alone, and with the combination of insulin and sulfonylureas and metformin. Pramlintide can be used in combination with insulin, but it cannot replace insulin.